JP7516369B2 - トランスサイトーシスのための送達構築物および関連する方法 - Google Patents
トランスサイトーシスのための送達構築物および関連する方法 Download PDFInfo
- Publication number
- JP7516369B2 JP7516369B2 JP2021525169A JP2021525169A JP7516369B2 JP 7516369 B2 JP7516369 B2 JP 7516369B2 JP 2021525169 A JP2021525169 A JP 2021525169A JP 2021525169 A JP2021525169 A JP 2021525169A JP 7516369 B2 JP7516369 B2 JP 7516369B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- delivery construct
- amino acid
- acid sequence
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024107251A JP2024127939A (ja) | 2018-11-07 | 2024-07-03 | トランスサイトーシスのための送達構築物および関連する方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756889P | 2018-11-07 | 2018-11-07 | |
| US62/756,889 | 2018-11-07 | ||
| PCT/US2019/021474 WO2019173787A1 (en) | 2018-03-08 | 2019-03-08 | Toxin-derived delivery constructs for oral delivery |
| USPCT/US2019/021474 | 2019-03-08 | ||
| US201962888133P | 2019-08-16 | 2019-08-16 | |
| US201962888238P | 2019-08-16 | 2019-08-16 | |
| US62/888,133 | 2019-08-16 | ||
| US62/888,238 | 2019-08-16 | ||
| PCT/US2019/050708 WO2020096695A1 (en) | 2018-11-07 | 2019-09-11 | Cholix-derived carriers for oral delivery of heterologous payload |
| USPCT/US2019/050708 | 2019-09-11 | ||
| PCT/US2019/060356 WO2020097394A1 (en) | 2018-11-07 | 2019-11-07 | Delivery constructs for transcytosis and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024107251A Division JP2024127939A (ja) | 2018-11-07 | 2024-07-03 | トランスサイトーシスのための送達構築物および関連する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506990A JP2022506990A (ja) | 2022-01-17 |
| JP2022506990A5 JP2022506990A5 (cg-RX-API-DMAC7.html) | 2022-11-01 |
| JP7516369B2 true JP7516369B2 (ja) | 2024-07-16 |
Family
ID=70612266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525169A Active JP7516369B2 (ja) | 2018-11-07 | 2019-11-07 | トランスサイトーシスのための送達構築物および関連する方法 |
| JP2024107251A Pending JP2024127939A (ja) | 2018-11-07 | 2024-07-03 | トランスサイトーシスのための送達構築物および関連する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024107251A Pending JP2024127939A (ja) | 2018-11-07 | 2024-07-03 | トランスサイトーシスのための送達構築物および関連する方法 |
Country Status (21)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| PL3762009T3 (pl) | 2018-03-08 | 2022-09-12 | Applied Molecular Transport Inc. | Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego |
| SG11202104734YA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
| ES2911075T3 (es) | 2018-11-07 | 2022-05-17 | Applied Molecular Transport Inc | Constructos de administración para transcitosis y métodos relacionados |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| US20240050559A1 (en) * | 2020-06-09 | 2024-02-15 | Icosavax, Inc. | Method of making virus-like particle |
| WO2022177644A1 (en) * | 2021-02-16 | 2022-08-25 | Applied Molecular Transport Inc. | Methods for treating spondyloarthropathies and related compositions |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500967A (ja) | 2006-07-20 | 2010-01-14 | ザ ジェネラル ホスピタル コーポレイション | コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット |
| JP2010534061A (ja) | 2007-07-20 | 2010-11-04 | ザ ジェネラル ホスピタル コーポレイション | 組換えコレラ菌外毒素 |
| JP2013541523A (ja) | 2010-09-15 | 2013-11-14 | マースニー,ランドル,ジェイ | 細菌毒素由来輸送配列を使用する生物活性剤の送達の系および方法 |
| JP2017519039A (ja) | 2014-05-07 | 2017-07-13 | アプライド モルキュラー トランスポート リミテッド ライアビリティー カンパニーApplied Molecular Transport Llc | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US6051405A (en) | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| DE60136281D1 (de) * | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| ATE442858T1 (de) | 2000-11-27 | 2009-10-15 | Powderject Vaccines Inc | Nukleinsäureadjuvantien |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| CA2447795A1 (en) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| KR20060022289A (ko) * | 2003-06-23 | 2006-03-09 | 제네틱스 인스티튜트, 엘엘씨 | 인터류킨-22 에 대한 항체 및 그의 용도 |
| EP1522585A1 (en) | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
| WO2006135428A2 (en) | 2004-10-04 | 2006-12-21 | Trinity Biosystems, Inc. | Methods and compositions for inducing an immune response against multiple antigens |
| US7713737B2 (en) | 2004-10-04 | 2010-05-11 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
| US20090148401A1 (en) | 2005-12-05 | 2009-06-11 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| CA2669094A1 (en) | 2006-11-08 | 2008-05-29 | Novavax,Inc. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| US20110250199A1 (en) | 2008-06-04 | 2011-10-13 | The Government of the United States of America as represented by the Secretary of the Department.... | Immunotoxins and uses thereof |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| SG176963A1 (en) * | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
| EP2456470A1 (en) | 2009-07-22 | 2012-05-30 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2012101235A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| ES2773115T3 (es) | 2011-06-29 | 2020-07-09 | Rani Therapeutics Llc | Preparados de agentes terapéuticos para la administración hacia el interior de una luz del tubo intestinal utilizando un dispositivo tragable para la administración de fármacos |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| AU2014346554B2 (en) | 2013-11-07 | 2020-06-04 | Evive Biotechnology (Shanghai) Ltd | Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
| JP6641280B2 (ja) | 2014-01-09 | 2020-02-05 | サノフイSanofi | インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤 |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN107108712A (zh) * | 2014-12-23 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 提高重组蛋白产量的方法 |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| US11523772B2 (en) | 2016-12-14 | 2022-12-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CA3093386A1 (en) * | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| SG11202104734YA (en) | 2018-11-07 | 2021-06-29 | Applied Molecular Transport Inc | Cholix-derived carriers for oral delivery of heterologous payload |
| ES2911075T3 (es) | 2018-11-07 | 2022-05-17 | Applied Molecular Transport Inc | Constructos de administración para transcitosis y métodos relacionados |
-
2019
- 2019-11-07 ES ES19207825T patent/ES2911075T3/es active Active
- 2019-11-07 PL PL19207825T patent/PL3650037T3/pl unknown
- 2019-11-07 BR BR112021009003-7A patent/BR112021009003A2/pt unknown
- 2019-11-07 SG SG11202104721RA patent/SG11202104721RA/en unknown
- 2019-11-07 WO PCT/US2019/060356 patent/WO2020097394A1/en not_active Ceased
- 2019-11-07 EP EP22159495.5A patent/EP4083058A3/en not_active Withdrawn
- 2019-11-07 CA CA3119060A patent/CA3119060A1/en active Pending
- 2019-11-07 DK DK19207825.1T patent/DK3650037T3/da active
- 2019-11-07 CN CN201980088287.9A patent/CN113423722A/zh active Pending
- 2019-11-07 AU AU2019377117A patent/AU2019377117B2/en active Active
- 2019-11-07 KR KR1020217017210A patent/KR20210110294A/ko active Pending
- 2019-11-07 MX MX2021005346A patent/MX2021005346A/es unknown
- 2019-11-07 TW TW108140533A patent/TW202031678A/zh unknown
- 2019-11-07 JP JP2021525169A patent/JP7516369B2/ja active Active
- 2019-11-07 EA EA202191280A patent/EA202191280A1/ru unknown
- 2019-11-07 PT PT192078251T patent/PT3650037T/pt unknown
- 2019-11-07 EP EP19207825.1A patent/EP3650037B1/en active Active
- 2019-11-18 US US16/686,671 patent/US20200140511A1/en not_active Abandoned
-
2020
- 2020-06-15 US US16/902,256 patent/US11027020B2/en active Active
-
2021
- 2021-04-20 US US17/235,567 patent/US20210338828A1/en not_active Abandoned
- 2021-05-06 IL IL282987A patent/IL282987B2/en unknown
- 2021-05-07 CL CL2021001209A patent/CL2021001209A1/es unknown
- 2021-06-07 CO CONC2021/0007402A patent/CO2021007402A2/es unknown
-
2022
- 2022-05-11 CY CY20221100326T patent/CY1125216T1/el unknown
-
2023
- 2023-09-01 US US18/241,744 patent/US20240238429A1/en not_active Abandoned
-
2024
- 2024-07-03 JP JP2024107251A patent/JP2024127939A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500967A (ja) | 2006-07-20 | 2010-01-14 | ザ ジェネラル ホスピタル コーポレイション | コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット |
| JP2010534061A (ja) | 2007-07-20 | 2010-11-04 | ザ ジェネラル ホスピタル コーポレイション | 組換えコレラ菌外毒素 |
| JP2013541523A (ja) | 2010-09-15 | 2013-11-14 | マースニー,ランドル,ジェイ | 細菌毒素由来輸送配列を使用する生物活性剤の送達の系および方法 |
| JP2017519039A (ja) | 2014-05-07 | 2017-07-13 | アプライド モルキュラー トランスポート リミテッド ライアビリティー カンパニーApplied Molecular Transport Llc | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210338828A1 (en) | 2021-11-04 |
| EP3650037A1 (en) | 2020-05-13 |
| AU2019377117A1 (en) | 2021-06-10 |
| EA202191280A1 (ru) | 2021-12-27 |
| CA3119060A1 (en) | 2020-05-14 |
| IL282987B (en) | 2022-10-01 |
| EP3650037B1 (en) | 2022-03-02 |
| US20240238429A1 (en) | 2024-07-18 |
| CN113423722A (zh) | 2021-09-21 |
| BR112021009003A2 (pt) | 2021-08-17 |
| PT3650037T (pt) | 2022-06-27 |
| KR20210110294A (ko) | 2021-09-07 |
| MX2021005346A (es) | 2021-10-13 |
| TW202031678A (zh) | 2020-09-01 |
| CO2021007402A2 (es) | 2021-09-30 |
| US20200140511A1 (en) | 2020-05-07 |
| JP2024127939A (ja) | 2024-09-20 |
| SG11202104721RA (en) | 2021-06-29 |
| AU2019377117B2 (en) | 2025-05-29 |
| PL3650037T3 (pl) | 2022-06-06 |
| US11027020B2 (en) | 2021-06-08 |
| EP4083058A3 (en) | 2023-01-11 |
| WO2020097394A1 (en) | 2020-05-14 |
| JP2022506990A (ja) | 2022-01-17 |
| ES2911075T3 (es) | 2022-05-17 |
| EP4083058A2 (en) | 2022-11-02 |
| US20200306383A1 (en) | 2020-10-01 |
| CY1125216T1 (el) | 2024-12-13 |
| DK3650037T3 (da) | 2022-05-02 |
| CL2021001209A1 (es) | 2021-11-19 |
| IL282987B2 (en) | 2023-02-01 |
| IL282987A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024127939A (ja) | トランスサイトーシスのための送達構築物および関連する方法 | |
| US20250388641A1 (en) | Novel interleukin-15 (il-15) fusion proteins and uses thereof | |
| JP5876034B2 (ja) | Pcsk9に結合するフィブロネクチンベースのスカフォールドドメインタンパク質 | |
| Seo et al. | Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins | |
| MX2012009050A (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23). | |
| CN108350054A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| JP2022506990A5 (cg-RX-API-DMAC7.html) | ||
| CN110121355A (zh) | 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物 | |
| CN117298254A (zh) | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 | |
| IL305625A (en) | Stable formulations of proteins based on the scaffolding region of fibronectin that bind to myostatin | |
| JP2015512902A (ja) | 経口投与 | |
| CN111601815A (zh) | 靶向细胞中c-Myc的嵌合分子 | |
| JP2023512337A (ja) | インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 | |
| EA043603B1 (ru) | Конструкции для доставки для трансцитоза и связанные способы | |
| ES2728446T3 (es) | Proteínas de fusión de P-anticuerpos de amiloide sérico | |
| HK40029390A (en) | Delivery constructs for transcytosis and related methods | |
| HK40029390B (en) | Delivery constructs for transcytosis and related methods | |
| Wang et al. | Rational and efficient preparation of a chimeric protein containing a tandem dimer of thrombopoietin mimetic peptide fused to human growth hormone in Escherichia coli | |
| Zhang et al. | Extending the in vivo Half-Life of Adalimumab Fab via Sortase A-Mediated Conjugation of Adalimumab Fab with Modified Fatty Acids | |
| WO2023237935A2 (en) | Methods for treating acute conditions using lipid binding protein-based complexes | |
| HK40091844A (en) | Dual function proteins and pharmaceutical composition comprising same | |
| WO2024193713A1 (zh) | 一种二价il-17治疗性疫苗及其制备方法和应用 | |
| HK40086042A (en) | Dual function proteins and pharmaceutical composition comprising same | |
| HK40101761A (en) | A super-trail molecule comprising two trail trimers | |
| JP2020033372A (ja) | 経口投与 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230925 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240604 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240703 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7516369 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |